<DOC>
	<DOCNO>NCT01130259</DOCNO>
	<brief_summary>The following trial design offer pre-approval drug access iniparib combination gemcitabine carboplatin order provide potential clinical benefit patient ER- , PR- , HER2-negative metastatic breast cancer . This follow ongoing Phase 3 , multi-center , open-label , randomize study gemcitabine/carboplatin , without iniparib , patient ER- , PR- , HER2-negative metastatic breast cancer ( protocol 20090301 ) . Based data generate BiPar/Sanofi , conclude iniparib posse characteristic typical PARP inhibitor class . The exact mechanism yet fully elucidate , however base experiment tumor cell perform laboratory , iniparib novel investigational anti-cancer agent induces gamma-H2AX ( marker DNA damage ) tumor cell line , induces cell cycle arrest G2/M phase tumor cell line , potentiates cell cycle effect DNA damage modality tumor cell line . Investigations potential target iniparib metabolite ongoing .</brief_summary>
	<brief_title>An Open-Label , Expanded Access Protocol Iniparib Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Iniparib</mesh_term>
	<criteria>Histologically document breast cancer ( either primary metastatic site ) ERnegative , PRnegative , HER2 nonover express immunohistochemistry ( 0 , 1 ) situ hybridization ( ISH ) include ; fluorescence ( FISH ) situ hybridization / chromogenic situ hybridization ( CISH ) ratio &lt; 2.0 One three prior chemotherapy regimen metastatic setting . Prior adjuvant/neoadjuvant therapy allow . Prior Gemcitabine and/or Platinum agent allow . Metastatic breast cancer ( Stage IV ) Female , ≥18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Organ marrow function follow : absolute neutrophil count ( ANC ) ≥1500/mm3 , platelet ≥100,000/dL , hemoglobin ≥9 g/dL , bilirubin ≤1.5 mg/dL , serum creatinine ≤1.5 mg/dL creatinine clearance ≥60 mL/min , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time upper limit normal liver involvement ≤5 time upper limit normal liver involvement For woman child bear potential , documented negative pregnancy test within two week EAP entry agreement acceptable birth control duration EAP therapy Capability understand comply protocol sign informed consent document Systemic anticancer therapy within 14 day first dose study drug Has recover grade ≤1 adverse event ( AEs ) per National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) v3.0 , exception alopecia , related anticancer therapy prior first dose study drug Major medical condition might affect EAP participation ( e.g . uncontrolled pulmonary , renal , hepatic dysfunction , uncontrolled infection , cardiac disease ) Brain metastases require steroid expect require therapeutic intervention study participation , include WBRT intrathecal therapy . Patients must &gt; 21days neurosurgical intervention Pregnant breastfeeding Inability unwillingness abide EAP protocol cooperate fully investigator designee Enrollment limit determine validated RandomSelection Process administer NORD ( National Organization Rare Disorders ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>mTNBC</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>metastatic triple negative breast cancer</keyword>
	<keyword>metastatic breast cancer ER- , PR- , HER2-negative</keyword>
</DOC>